Antibodies targeting CTLA-4 are used to boost anti-tumor immunity1 while soluble CTLA-4 molecules, that outcompete CD28 for access to their shared ligands CD80 and CD86, are used in autoimmune settings2,3. This evidence concerns the gene CTLA4 and neoplasm.